Objectives: This study focuses on the development of a dry powder inhaler (DPI) formulation of @entity3413 (SV), and the effects of SV on the respiratory epithelium. Methods: Micronised SV samples were prepared by dry jet-milling. The long-term chemical stability and physicochemical properties of the formulations were characterised in terms of particles size, morphology, thermal and moisture responses. Furthermore, in vitro aerosol depositions were performed. The formulation was evaluated for cell viability and its effect on cilia beat activity, using ciliated nasal epithelial cells in vitro. The formulation transport across an established air interface @entity1 bronchial epithelial cells and its ability to reduce mucus secretion was also investigated. Results: The particle size of the SV formulation and its aerosol performance were appropriate for inhalation therapy. Moreover, the formulation was found to be non-toxic to pulmonary epithelia cells and cilia beat activity up to a concentration of 10(-6) M. Transport studies revealed that SV has the ability to penetrate into airway epithelial cells and is converted into its active SV @entity32702 metabolite. Single dose of SV DPI also decreased mucus production after 4 days of dosing. Conclusion: This therapy could potentially be used for the local treatment of diseases like @entity1030 , @entity1577 , and @entity4595 given its anti-inflammatory effects and ability to reduce mucus production.

Dry powder formulation of XXXX .

@entity1 :: ('9606', 'Species') :: ['Calu-3'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin'] @entity32702 :: ('CHEBI:35868', 'Chemical') :: ['hydroxy acid'] @entity4595 :: ('MESH:D001987', 'Disease') :: ['bronchiectasis'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['cystic fibrosis']
@entity3413 :: (MESH:D019821,Chemical) :: ['simvastatin']
